PSMA PET-CT Scanning for Prostate Cancer: What It Shows, When It Is Used and What the Results Mean

A urological surgeon’s guide to PSMA PET-CT for men being investigated or treated for prostate cancer.

PSMA PET-CT has transformed the way prostate cancer is staged and investigated after treatment.

Compared with conventional CT and isotope bone scanning, it can identify much smaller deposits of prostate cancer in lymph nodes, bones and other parts of the body. It can help doctors determine whether cancer is still confined to the prostate, locate disease when the PSA rises after treatment and identify patients who may be suitable for PSMA-targeted radioligand therapy.

However, PSMA PET-CT is not infallible.

A more sensitive scan can provide more information, but more information does not always make the correct treatment decision obvious. Small areas of uptake can be benign, microscopic cancer can remain invisible, and we do not yet know whether treating every additional abnormality found on a highly sensitive scan improves survival.

The most useful question is therefore not simply:

“Can a PSMA PET-CT find something?”

It is:

“Will the result change what we should do?”

This guide explains how PSMA PET-CT works, when it is most useful, what positive and negative results mean, how it compares with MRI, who may qualify for an NHS scan and where the limitations lie.

PSMA PET-CT at a glance

PSMA PET-CT is a whole-body molecular imaging test used principally in prostate cancer.

Its most established uses are:

staging newly diagnosed higher-risk prostate cancer;
locating recurrent cancer when the PSA rises after surgery or radiotherapy;
helping plan salvage radiotherapy;
assessing apparently limited or oligometastatic disease;
and determining eligibility for PSMA-targeted radioligand treatment.

It is more sensitive than conventional CT and bone scanning for many forms of prostate cancer spread. However, a negative scan cannot exclude microscopic cancer, and a positive area of uptake is not always cancer.

PSMA PET-CT complements prostate MRI and biopsy rather than replacing them.

What is a PET-CT scan?

PET-CT combines two different types of imaging in one examination.

PET imaging

PET stands for positron emission tomography.

Before the scan, a small amount of a radioactive tracer is injected into a vein. The tracer circulates through the body and accumulates preferentially in tissues expressing a particular biological target.

The scanner detects the radiation emitted by the tracer and produces a three-dimensional map showing where it has collected.

Unlike a conventional scan that mainly shows structure, PET imaging provides information about the molecular or metabolic activity of tissues.

CT imaging

CT stands for computed tomography.

CT uses X-rays to produce detailed anatomical images of the skeleton, lymph nodes, organs and soft tissues.

The PET signal is then superimposed on the CT image. This allows the reporting specialist to see both:

where an abnormal area is located; and
whether it is showing increased tracer uptake.

For example, a lymph node measuring only 4 mm may look entirely unremarkable on CT because it is not enlarged. If it shows intense PSMA uptake on the PET component, however, it may represent a small deposit of prostate cancer.

What does PSMA mean?

PSMA stands for prostate-specific membrane antigen.

It is a protein found on the surface of prostate cells. PSMA is usually expressed at much higher levels by prostate cancer cells, particularly in higher-grade, recurrent, metastatic and castration-resistant disease.

Despite its name, PSMA is not found exclusively in prostate cancer. It can also be expressed in normal tissues, benign conditions and the blood vessels of several other tumours.

That is why PSMA PET-CT findings must always be interpreted in context.

A PSMA-targeting molecule is attached to a small amount of radioactive material. Once injected, it binds to cells expressing PSMA. The PET scanner then detects where the tracer has accumulated.

The result is effectively a whole-body map of PSMA expression.

A licensed gallium-68 PSMA diagnostic product is available in the UK, although the regulatory status and preparation arrangements vary between individual tracers and centres.

Why ordinary FDG PET is less useful in prostate cancer

The tracer most commonly used for PET imaging in other cancers is fluorodeoxyglucose, usually called FDG.

FDG is a radiolabelled form of glucose. Many cancers consume large quantities of glucose and therefore show increased FDG uptake.

Most conventional prostate adenocarcinomas are different. They may grow and spread without being particularly glucose-hungry, especially earlier in the disease course. As a result, ordinary FDG PET is often relatively insensitive for typical prostate cancer.

FDG PET may still be useful in selected patients with:

aggressive or poorly differentiated disease;
neuroendocrine or small-cell prostate cancer;
advanced cancer that has lost PSMA expression;
or findings that appear discordant on a PSMA scan.

The development of tracers targeting PSMA therefore provided prostate cancer with a far more disease-specific form of PET imaging.

Which PSMA tracers are used?

Several PSMA-targeting tracers are in clinical use.

The tracer you receive will depend on the centre, local radiopharmacy arrangements, supply and the particular clinical question.

Gallium-68 PSMA

Gallium-68 PSMA-11 was one of the first extensively studied and widely adopted PSMA tracers.

It is mainly excreted through the kidneys and urinary system. This produces activity within the ureters and bladder.

That urinary activity can occasionally make it more difficult to assess a very small recurrence close to the bladder, particularly in the prostate bed after radical prostatectomy.

Gallium-68 gozetotide is licensed in the UK for identifying PSMA-positive lesions in adults with prostate cancer.

Fluorine-18 PSMA tracers

Fluorine-18 has a longer radioactive half-life than gallium-68. It can therefore be manufactured centrally and transported to scanning centres, which can improve availability.

Common fluorine-18 agents include:

F-18 PSMA-1007;
and F-18 DCFPyL, also called piflufolastat.

F-18 PSMA-1007 has relatively little urinary excretion and may therefore provide clearer views of the pelvis and prostate bed.

Its principal limitation is a recognised tendency to show small, non-cancerous areas of bone uptake. These may occur in ribs, the pelvis or other bones and can create uncertainty if they are interpreted without appropriate experience.

F-18 DCFPyL is excreted more through the urinary system and behaves more like gallium-68 PSMA-11 in that respect.

Is one tracer better than another?

There is no universally superior tracer for every patient.

The best choice depends on:

the reason for scanning;
whether the prostate is still present;
whether the question concerns the prostate bed;
the likelihood of bone disease;
and local reporting expertise.

In practice, the experience of the nuclear medicine physician or radiologist interpreting the examination may matter more than small differences between tracers.

Choline PET-CT

Radiolabelled choline was used before PSMA PET became widely available.

Choline PET-CT can detect prostate cancer because choline metabolism is increased in some prostate cancer cells. However, it is less sensitive than PSMA PET, particularly at lower PSA levels.

It is now generally used as an alternative where PSMA imaging is unavailable or unsuitable.

When is PSMA PET-CT used in prostate cancer?

PSMA PET-CT is most valuable when its result can alter treatment.

There are several important clinical settings.

1. Staging newly diagnosed prostate cancer

Staging means determining whether cancer is:

confined to the prostate;
growing immediately outside it;
involving nearby lymph nodes;
or spreading to bones or other organs.

Accurate staging is particularly important in men with higher-risk disease because it can determine whether treatment should involve:

radical prostatectomy;
radiotherapy to the prostate;
radiotherapy to the prostate and pelvic lymph nodes;
hormone treatment;
systemic therapy;
or a combination of treatments.

How accurate is PSMA PET-CT?

The landmark proPSMA trial compared PSMA PET-CT with conventional CT and isotope bone scanning in men with high-risk prostate cancer who were being considered for curative treatment.

PSMA PET-CT achieved an overall accuracy of approximately 92% for detecting pelvic nodal or distant metastatic disease, compared with approximately 65% for conventional imaging.

It also resulted in fewer uncertain findings and exposed patients to less radiation than the combined conventional CT-and-bone-scan pathway.

Current European guidance recommends PSMA PET-CT where available for metastatic screening in high-risk localised and locally advanced prostate cancer. The 2026 EAU guidance also supports its use in selected unfavourable intermediate-risk disease.

How can the result change treatment?

Consider a man whose MRI and biopsy suggest aggressive but apparently localised cancer.

If PSMA PET-CT finds no evidence of spread, radical surgery or radical radiotherapy may remain appropriate.

If it identifies several involved pelvic lymph nodes, treatment may shift towards:

radiotherapy covering the prostate and pelvic lymph nodes;
a longer course of androgen deprivation therapy;
additional systemic treatment;
or planned multimodal treatment.

If it identifies clear distant metastases, treatment is likely to become predominantly systemic rather than relying on treatment directed only at the prostate.

Does more accurate staging improve survival?

This remains an important unanswered question.

The proPSMA trial showed that PSMA PET-CT staged cancer more accurately. It was not designed to prove that changing treatment according to the additional findings makes men live longer.

It is reasonable to expect that more accurate information should improve treatment selection. However, that assumption should not be confused with definitive survival evidence.

PSMA PET-CT should therefore be used to inform clinical judgement, not replace it.

2. A rising PSA after radical prostatectomy

After complete surgical removal of the prostate, the PSA should usually fall to a very low or undetectable level.

A confirmed rising PSA after radical prostatectomy suggests that prostate cancer cells remain somewhere in the body. This is called biochemical recurrence.

The critical question is where those cells are located.

Possible sites include:

the prostate bed;
pelvic lymph nodes;
lymph nodes higher in the abdomen;
bones;
or more than one of these areas.

Why is the location important?

If recurrence is confined to the prostate bed or nearby pelvis, salvage radiotherapy may offer a further chance of long-term cancer control or cure.

If cancer has spread beyond the pelvis, prostate-bed radiotherapy alone may be insufficient. Treatment may need to include:

systemic hormonal treatment;
radiotherapy to additional sites;
metastasis-directed treatment;
or a combined strategy.

PSMA PET detection depends on the PSA level

The ability of PSMA PET-CT to identify recurrent disease generally increases as the PSA rises.

Approximate detection rates reported across studies are:

around one-third to one-half when PSA is between 0.2 and 0.5 ng/mL;
approximately 50–70% between 0.5 and 1.0 ng/mL;
higher again between 1 and 2 ng/mL;
and above 90% in many series once PSA exceeds 2 ng/mL.

These are broad estimates rather than guarantees. Detection also depends on:

PSA doubling time;
tumour grade;
previous treatment;
the tracer used;
and the quality of the equipment and reporting.

What does a negative scan at a low PSA mean?

A negative scan does not prove that no cancer remains.

At a PSA of 0.2 or 0.3 ng/mL, the volume of recurrent cancer may simply be below the spatial resolution of the scanner.

This is one of the most important points for patients to understand:

A negative PSMA PET-CT means that no disease was detectable on that scan. It does not mean that no cancer cells are present.

Early salvage radiotherapy is generally more effective when delivered at a low PSA. It may therefore be inappropriate to delay potentially curative treatment simply to wait for the scan to become positive.

The 2026 EAU guideline recommends PSMA PET-CT after prostatectomy when PSA is above 0.2 ng/mL if the result is likely to influence subsequent treatment decisions.

3. A rising PSA after radiotherapy

PSA behaves differently after radiotherapy because the prostate remains in place.

The PSA often falls gradually and does not usually become completely undetectable. It may also fluctuate temporarily.

Biochemical recurrence after radiotherapy is conventionally defined as a PSA rise of at least 2 ng/mL above the lowest PSA reached after treatment.

When recurrence is suspected, PSMA PET-CT may help determine whether disease is:

still confined to the prostate;
present in seminal vesicles;
involving pelvic lymph nodes;
or present at distant sites.

This matters because selected men with genuinely local recurrence may be considered for further local treatment, including:

salvage prostatectomy;
cryotherapy;
high-intensity focused ultrasound;
brachytherapy;
or stereotactic radiotherapy.

These treatments can carry significant side effects and should only be considered after careful restaging, prostate MRI, biopsy confirmation where appropriate and multidisciplinary review.

4. Planning salvage radiotherapy

PSMA PET-CT may influence both whether salvage radiotherapy is offered and where it is directed.

The scan may show:

no visible disease;
recurrence limited to the prostate bed;
one or more pelvic lymph nodes;
lymph nodes outside the standard pelvic field;
or distant metastatic disease.

A positive pelvic lymph node may lead the clinical oncologist to expand the radiotherapy field or boost the dose to the abnormal node.

A negative scan at a low PSA, however, does not exclude microscopic disease within the prostate bed. In that situation, treatment may still proceed on the basis of PSA behaviour, original pathology and the probability of microscopic local recurrence.

The decision should not be made by the scan result alone.

5. Oligometastatic prostate cancer

The word oligometastatic describes cancer that has spread to a limited number of sites rather than being widely metastatic.

There is no single universally accepted definition. In many studies, it means between one and three or one and five metastatic deposits.

The concept of oligometastatic cancer predates PSMA PET, but PSMA imaging has transformed our ability to identify small-volume metastatic prostate cancer.

A man whose conventional CT and bone scan appear normal may have one or two small PSMA-positive lymph nodes or bone lesions.

This has led to increasing use of metastasis-directed therapy, such as:

stereotactic body radiotherapy to an isolated bone deposit;
stereotactic radiotherapy to an involved lymph node;
or, in selected circumstances, surgical lymph-node treatment.

Can treating every visible metastasis cure the cancer?

Not necessarily.

PSMA PET-CT can reveal what is visible today, but microscopic disease may exist elsewhere.

Trials suggest that metastasis-directed therapy can delay further progression and may postpone the need for long-term systemic treatment in selected men. However, many studies are relatively small, and long-term survival benefits remain less certain.

Treatment should therefore be discussed within a specialist multidisciplinary team. Clinical trial participation should be considered where available.

6. Selecting patients for PSMA radioligand therapy

PSMA is not only an imaging target. It can also be used to deliver treatment directly to prostate cancer cells.

This approach is called theranostics:

a diagnostic tracer identifies cells expressing PSMA;
and a therapeutic radioactive substance targets the same protein.

What is lutetium-177 PSMA therapy?

Lutetium-177 vipivotide tetraxetan, marketed as Pluvicto, binds to PSMA-expressing cells and delivers beta radiation over a short distance.

The VISION trial showed improved progression-free and overall survival in men with PSMA-positive metastatic castration-resistant prostate cancer who had previously received androgen-receptor pathway treatment and taxane chemotherapy.

PSMA PET imaging is used to confirm that the cancer expresses enough PSMA for treatment to be appropriate.

The UK marketing authorisation has subsequently expanded to include selected men with PSMA-positive metastatic castration-resistant disease who have progressed after an androgen-receptor pathway inhibitor and are considered suitable for delaying taxane chemotherapy.

Is Pluvicto routinely available through the NHS?

Regulatory approval and NHS funding are separate decisions.

NICE did not recommend lutetium-177 vipivotide tetraxetan for routine NHS use in its earlier appraisal of men treated after an androgen receptor pathway inhibitor and taxane chemotherapy, or where taxanes were medically unsuitable. NICE concluded that the most likely cost-effectiveness estimates exceeded the range normally considered an acceptable use of NHS resources.

Further NICE appraisals of newer indications are in development or awaiting development. Therefore, the position may change.

At present, access may depend on:

private funding;
clinical-trial availability;
individual NHS arrangements;
or treatment in another country.

Any man considering PSMA radioligand treatment should obtain specialist advice about clinical suitability, realistic benefits, potential adverse effects and the total financial cost.

7. Could PSMA PET-CT reduce the need for prostate biopsy?

This is an important emerging area.

At present, prostate MRI remains the main imaging investigation used to decide whether a prostate biopsy is required. However, MRI does not give a clear answer in every patient.

Some men have:

a persistently raised or rising PSA;
significant clinical risk factors;
but only equivocal or relatively non-suspicious MRI findings.

The PRIMARY2 trial investigated whether PSMA PET-CT could help avoid unnecessary biopsies in this group.

The study included 660 biopsy-naïve men with PI-RADS 2 or 3 MRI findings and additional clinical risk factors. Men assigned to the PSMA PET strategy could avoid immediate biopsy when the scan was reassuring.

Approximately half of the men in the PSMA PET group avoided biopsy. Detection of clinically significant prostate cancer was not meaningfully reduced, while the diagnosis of clinically insignificant cancer fell substantially.

These results are promising because unnecessary biopsy can lead to:

discomfort;
bleeding or infection;
anxiety;
and the diagnosis of low-grade cancers that may never cause harm.

However, this is not yet standard routine practice in the UK, and PSMA PET-CT is not currently a general replacement for prostate biopsy.

Imaging cannot provide a Gleason score or Grade Group. Tissue remains necessary to confirm the diagnosis and determine the biological grade of the cancer before most treatments.

PSMA PET-CT versus MRI: which is better?

Neither test is universally better because they answer different questions.

Multiparametric MRI is primarily used to assess:

whether a suspicious lesion is present within the prostate;
where a biopsy should be targeted;
the relationship between a tumour and the prostate capsule;
possible seminal-vesicle involvement;
and local anatomy.

PSMA PET-CT is primarily used to assess:

whether prostate cancer has spread to lymph nodes;
whether there are bone or distant metastases;
where recurrent disease may be located;
and whether advanced cancer expresses PSMA strongly enough for targeted treatment.

MRI generally provides better anatomical detail within and immediately around the prostate. PSMA PET-CT generally provides better whole-body molecular staging.

In many men, the tests are complementary rather than competing.

Can PSMA PET-CT replace a prostate biopsy?

No—not in routine current practice.

A scan may show an area that is highly suspicious for prostate cancer, but imaging cannot reliably provide:

a Gleason pattern;
a Grade Group;
the presence of cribriform or intraductal cancer;
or other microscopic features that influence prognosis and treatment.

A biopsy provides tissue that can be examined by a specialist uropathologist.

PSMA PET-CT may increasingly help determine who needs a biopsy and where the biopsy should be targeted, but it does not yet generally replace histological confirmation.

What happens during a PSMA PET-CT scan?

The procedure is relatively straightforward.

Before the scan

Most PSMA PET scans do not require fasting.

You will usually be advised to:

drink water before the appointment;
remain well hydrated;
bring an up-to-date medication list;
and follow any specific instructions from the nuclear medicine department.

Tell the team if you have recently started or stopped:

androgen deprivation therapy;
chemotherapy;
radiotherapy;
or another prostate cancer treatment.

Hormonal treatment can alter PSMA expression and may affect interpretation.

The injection

A small cannula is inserted into a vein, usually in the arm.

The radioactive tracer is injected intravenously. Most patients feel nothing unusual when it is administered.

Unlike some CT contrast injections, it does not normally produce a warm flush or metallic taste.

The uptake period

After the injection, you wait while the tracer circulates and binds to PSMA-expressing tissue.

The waiting period varies according to the tracer and local protocol but is commonly between approximately 60 and 120 minutes.

You may be encouraged to drink water and will usually be asked to empty your bladder before imaging.

The scan itself

You lie flat on the scanner bed, commonly with your arms raised above your head.

The scan usually covers most of the body, often from the mid-thigh to the skull base, although some centres use wider coverage depending on the clinical question and protocol.

Scanning commonly takes approximately 20–30 minutes.

The machine is a wide ring rather than the enclosed tunnel used for many MRI examinations. Most patients therefore find it less claustrophobic than MRI.

After the scan

You can usually:

eat and drink normally;
drive;
return home;
and resume ordinary activities.

You will be advised to drink extra fluid to help clear the tracer through the kidneys and bladder.

You may also be asked to avoid prolonged close contact with pregnant women and young children for a specified period. Follow the instructions given by the scanning department because these vary between tracers and administered doses.

How much radiation is involved?

A PSMA PET-CT exposes you to ionising radiation from both:

the radioactive PET tracer;
and the CT component.

The total dose varies according to the tracer, body size and whether the CT is a low-dose localisation scan or a full diagnostic CT.

A typical combined dose is broadly comparable with a diagnostic CT of the chest, abdomen and pelvis. It is commonly in the approximate region of 8–15 mSv, although individual protocols differ.

The radiopharmaceutical component alone may account for only part of that total. Professional guidance reports tracer doses that vary according to the agent used, with the CT protocol making a substantial additional contribution.

Radiation exposure should never be unnecessary. However, where the result will affect the management of a known or suspected cancer, the likely benefit generally outweighs the small theoretical long-term radiation risk.

How long do PSMA PET-CT results take?

Results are commonly available within several working days.

The precise timing depends on:

whether the scan was performed through the NHS or privately;
reporter availability;
whether comparison imaging is required;
and whether the findings need discussion at a multidisciplinary meeting.

A technically rapid report is not always better. Complex or equivocal findings may need review alongside:

MRI;
previous CT or bone scans;
operative pathology;
PSA history;
treatment dates;
and other clinical information.

The report should ideally be interpreted by a specialist with regular experience in prostate cancer molecular imaging.

Understanding a PSMA PET-CT report

PSMA PET reports may contain unfamiliar terminology.

PSMA avid

A lesion described as PSMA avid has taken up more tracer than the surrounding tissue.

This does not automatically prove that it is cancer. The location, shape, intensity and corresponding appearance on CT or MRI must also be considered.

SUVmax

SUV stands for standardised uptake value.

SUVmax is a semi-quantitative estimate of the highest tracer concentration within a lesion.

Higher uptake may be associated with greater PSMA expression, but absolute SUV values should not be interpreted in isolation. They are influenced by:

the tracer;
scanner;
uptake time;
reconstruction method;
body composition;
and other technical factors.

An SUV from one scan cannot always be compared directly with a value from another centre or tracer.

PRIMARY score

The PRIMARY score is a structured system used to describe patterns of PSMA uptake within the prostate.

It ranges from 1 to 5, with higher scores being more suspicious for clinically significant prostate cancer.

It is particularly relevant to the emerging use of PSMA PET in men who have not yet undergone biopsy.

PROMISE and miTNM

PROMISE is a standardised framework for reporting PSMA PET findings.

The associated molecular imaging TNM system, or miTNM, describes:

the prostate or prostate bed;
lymph-node involvement;
bone disease;
and other distant metastases.

Structured frameworks help clinicians communicate findings consistently.

PSMA-RADS

PSMA-RADS is a reporting system that classifies findings according to how likely they are to represent prostate cancer.

Indeterminate lesions may require:

comparison with earlier scans;
MRI or diagnostic CT;
targeted imaging;
interval follow-up;
or occasionally biopsy.

The 2026 EAU guideline recognises the increasing use of harmonised reporting frameworks, including PROMISE, PRIMARY scoring and quantitative uptake measurements.

What are the limitations of PSMA PET-CT?

PSMA PET-CT is highly valuable, but it is not a perfect cancer detector.

False-positive PSMA uptake

PSMA is not exclusive to prostate cancer.

Normal uptake occurs in several tissues, including:

salivary glands;
lacrimal glands;
liver;
spleen;
kidneys;
bowel;
and urinary tract.

Benign conditions can also take up PSMA tracer.

Examples include:

sympathetic and coeliac ganglia;
healing rib fractures;
degenerative bone changes;
Paget’s disease;
fibrous dysplasia;
vertebral haemangiomas;
inflammation;
and granulomatous disease such as sarcoidosis.

PSMA expression can also occur in the tumour blood vessels of some other cancers, including renal, thyroid and liver tumours.

The licensed gallium-68 gozetotide product information specifically warns that uptake is not confined to prostate cancer and should be interpreted alongside histology and other diagnostic information.

Why solitary bone spots need caution

A single small focus in a rib is a common source of anxiety.

It may represent metastatic disease, but it may also reflect:

an old injury;
a healing fracture;
or non-specific uptake, particularly with some fluorine-18 tracers.

The likelihood that it is significant depends on the whole clinical picture:

prostate cancer grade;
PSA;
PSA doubling time;
other scan findings;
CT appearance;
symptoms;
and previous trauma.

An isolated equivocal focus should not automatically overturn an otherwise appropriate curative treatment plan.

False-negative scans

Some prostate cancers express very little PSMA.

This occurs in a minority of conventional prostate cancers but may be more common in:

neuroendocrine prostate cancer;
small-cell disease;
heavily pre-treated cancer;
and cancers that have dedifferentiated over time.

These tumours may be PSMA-negative but FDG-positive.

In addition, even strongly PSMA-expressing cancer will not be visible if the deposit is too small for the scanner to resolve.

A negative scan therefore means:

No PSMA-positive disease was detected above the resolution and sensitivity of that examination.

It does not mean that microscopic disease has been excluded.

Androgen deprivation therapy can affect uptake

Hormonal treatment may change PSMA expression.

Short-term androgen deprivation can sometimes increase PSMA uptake temporarily, while longer treatment may reduce uptake as responsive cancer cells shrink or become less active.

The relationship is complex and depends on:

the duration of treatment;
whether the cancer is hormone-sensitive or resistant;
and how well the disease is responding.

The reporting specialist must know the timing of hormone treatment in relation to the scan.

Stage migration

More sensitive imaging finds disease that older scans would have missed.

A man previously classified as having localised cancer may now be labelled as having metastatic disease because PSMA PET detects a tiny distant lesion.

This phenomenon is called stage migration.

It creates two important problems.

First, historical outcome figures may not apply directly. Men classified as having “localised” disease using modern PSMA staging represent a more carefully selected group than men classified using older CT and bone scanning.

Second, identifying additional disease does not automatically prove that treating every additional site improves survival.

The scan can tell us more about where cancer is. It cannot always tell us what the best response to that information should be.

Does a normal PSMA PET-CT mean the cancer has gone?

No.

A normal scan is reassuring, but it does not prove that every cancer cell has been eliminated.

A scan may be negative because:

no cancer remains;
the remaining disease is microscopic;
the PSA is too low for reliable localisation;
the cancer expresses little PSMA;
or treatment has suppressed tracer uptake.

PSA monitoring remains essential after treatment, regardless of the scan result.

Who can have PSMA PET-CT through the NHS in England?

NHS England published a routine commissioning policy for PSMA PET-CT in February 2025.

The commissioned criteria are narrower than many patients expect. The underlying principle is that NHS funding is provided when the scan is likely to change a potentially radical or salvage treatment decision.

Newly diagnosed high-risk prostate cancer

For primary staging, the policy covers men with high-risk prostate cancer who have equivocal abnormalities on baseline conventional imaging, where clarifying whether metastatic disease is present would alter management.

High-risk features include one or more of:

PSA above 20 ng/mL;
clinical stage T3 or above;
Gleason score 8 or above;
or Cambridge Prognostic Group 4 or 5.

The important qualification is that routine NHS commissioning does not necessarily provide PSMA PET-CT as the first staging test for every man with high-risk disease. Under the national policy, conventional imaging generally precedes it, with PSMA PET used to clarify uncertain findings.

Local NHS practice and access pathways may nevertheless vary.

Biochemical recurrence after prostatectomy

The commissioning criteria include:

PSA of at least 0.2 ng/mL;
a patient suitable for salvage treatment;
and a scan result expected to influence the management plan.

Biochemical recurrence after radiotherapy or brachytherapy

The criteria include:

a PSA rise of at least 2 ng/mL above the post-treatment nadir;
suitability for salvage local treatment;
and a result expected to change management.

Who may not qualify?

A scan may not be routinely funded when:

the patient is not suitable for further radical or salvage treatment;
the result would not affect treatment;
or the requested indication falls outside the commissioning policy.

The logic is not that the information would be uninteresting. It is that the NHS generally commissions the scan when it has a defined treatment consequence.

Can I have a PSMA PET-CT privately?

Yes.

PSMA PET-CT is available through a number of private hospitals and imaging providers in the UK.

A referral is normally required from a urologist, oncologist or another appropriately qualified clinician. The referring specialist should provide:

the diagnosis;
biopsy and pathology details;
PSA history;
previous treatment;
previous imaging;
current medication;
and the specific clinical question.

How much does a private PSMA PET-CT cost?

At the time of writing, advertised UK self-pay prices commonly fall in the approximate range of £3,000–£3,500.

The exact price may depend on:

the tracer;
the scanning centre;
whether a diagnostic CT is included;
whether contrast is required;
and whether specialist review or consultation is included.

Prices change, so obtain a written quotation before booking.

Private medical insurers may cover PSMA PET-CT when there is a clear indication, but prior authorisation is commonly required. Some policies apply criteria similar to the NHS policy.

Do not assume the scan will be reimbursed after it has already been performed.

Questions to ask before having a PSMA PET-CT

Before agreeing to the scan, ask your specialist:

1. What treatment decision will the result change?

This is the most important question.

A scan is most useful when there is a clear plan for:

a negative result;
a positive local result;
a positive nodal result;
and unexpected distant disease.

2. What happens if the scan is negative?

A negative scan may support a proposed treatment, but it may not rule out microscopic disease.

Ask whether treatment will proceed regardless of the result.

3. What happens if the scan shows one uncertain bone spot?

Discussing this possibility in advance helps prevent an equivocal finding from causing unnecessary alarm or delay.

4. Which tracer will be used?

The tracer may matter when assessing:

the prostate bed;
pelvic disease;
or isolated bone uptake.

5. Who will report the scan?

Ask whether the examination will be interpreted by a radiologist or nuclear medicine physician with regular experience in prostate cancer and PSMA imaging.

6. Will my case be discussed by a multidisciplinary team?

Complex results are often best interpreted by a team that includes:

urologists;
clinical oncologists;
medical oncologists;
radiologists;
nuclear medicine physicians;
and pathologists.

Frequently asked questions

Is PSMA PET-CT better than MRI?

They perform different roles.
MRI is generally better for examining the prostate itself, targeting biopsy and assessing local anatomy. PSMA PET-CT is generally better for looking for prostate cancer beyond the prostate.
Many men need both.

Can PSMA PET-CT detect all prostate cancer?

No.
Small-volume disease can be below the scanner’s resolution, and a minority of prostate cancers express little PSMA.

What PSA level is needed for a PSMA PET scan?

There is no single PSA level at which the scan becomes universally appropriate.
After prostatectomy, NHS commissioning generally begins at a PSA of 0.2 ng/mL when the patient is suitable for salvage treatment. However, detection rates are relatively modest at very low PSA levels.
The decision depends on whether the result will change treatment.

My PSA is 0.15 after prostatectomy. Should I have a PSMA scan?

Possibly, but not routinely in every case.
At a PSA below 0.2 ng/mL, the likelihood of a positive scan is lower. A negative result may not alter the need for early salvage radiotherapy.
Earlier imaging may nevertheless be considered when there are high-risk pathological findings or a rapidly increasing PSA. The decision should be individualised.

Does a negative PSMA PET mean I do not need radiotherapy?

No.
After prostatectomy, a negative low-PSA scan does not exclude microscopic cancer in the prostate bed.
Salvage radiotherapy may still be appropriate based on the PSA pattern and prostatectomy pathology.

Can inflammation cause PSMA uptake?

Yes.
Inflammation and a number of benign conditions can produce PSMA uptake. Findings must be assessed alongside the CT appearance, clinical history and distribution of disease.

Can benign prostate enlargement show on PSMA PET?

Some uptake may occur in benign prostate tissue. A PSMA scan should not be interpreted as a simple positive-or-negative cancer test.
MRI and biopsy remain important for diagnosing disease within the prostate.

Does PSMA PET-CT hurt?

No.
The only invasive part is insertion of a cannula for the injection. The scan itself is painless.

Will I feel radioactive afterwards?

You will retain a small amount of radioactivity for a short period.
You will normally be asked to drink plenty of fluid and limit prolonged close contact with pregnant women and young children for a specified time. Normal activities can otherwise usually continue.

Can I drive after the scan?

In most cases, yes.
The tracer does not normally impair alertness or driving ability. Follow any individual advice given by the scanning centre.

Can PSMA PET replace biopsy?

Not routinely.
PSMA PET may help select and target biopsies, but biopsy remains necessary to establish the Grade Group and microscopic characteristics of the cancer.

Can PSMA PET show whether treatment has worked?

It can be used in selected circumstances to assess response, particularly in advanced disease. However, PSA, conventional imaging, symptoms and clinical assessment remain important.
The timing and interpretation of repeat PSMA scans require specialist experience because treatment can alter PSMA expression.

Key points

PSMA PET-CT is a molecular imaging test developed specifically for prostate cancer.
It is substantially more accurate than conventional CT and bone scanning for staging many men with higher-risk disease.
Its most established roles are staging higher-risk prostate cancer and locating recurrence when the PSA rises after radical treatment.
A positive scan can alter surgery, radiotherapy fields, hormone treatment and systemic therapy.
A negative scan does not exclude microscopic prostate cancer.
PSMA uptake is not exclusive to prostate cancer, so false-positive findings occur.
MRI remains important for assessing the prostate and guiding biopsy.
Biopsy remains necessary to determine the Grade Group and microscopic features of the cancer.
NHS access in England is governed by specific commissioning criteria.
Regulatory approval of PSMA radioligand treatment does not automatically mean routine NHS funding.
The scan should be requested when the result is likely to change a meaningful treatment decision.

When should you seek specialist advice?

PSMA PET-CT may be relevant if you:

have recently been diagnosed with intermediate- or high-risk prostate cancer;
have uncertain findings on a CT or bone scan;
have a rising PSA after radical prostatectomy;
have a rising PSA after radiotherapy or brachytherapy;
are being assessed for salvage treatment;
have a small number of suspected metastatic deposits;
or are considering PSMA-targeted radioligand therapy.

The appropriate timing depends on your PSA, biopsy findings, previous treatment, general health and the treatment options that remain available.

The scan should form part of a wider clinical assessment rather than being ordered or interpreted in isolation.

About Mr Neil Haldar

Mr Neil Haldar is a Consultant Urological Surgeon specialising in prostate cancer, robotic and laparoscopic uro-oncology and complex urological surgery.

He provides specialist assessment and treatment for men with raised PSA, suspected or confirmed prostate cancer, and recurrent disease following previous treatment.

Medical disclaimer

This article is intended to provide general information and does not replace individual medical advice.

Decisions about prostate cancer imaging and treatment should be made with your own urologist, oncologist or multidisciplinary team, taking account of your diagnosis, pathology, PSA history, previous treatment, general health and personal priorities.

References

Mr Neil Haldar

Mr Neil Haldar is a UK Consultant Urological Surgeon specialising in prostate cancer, robotic surgery, uro-oncology and paediatric urology. He offers expert diagnosis, treatment and second opinions for complex urological conditions.